200 related articles for article (PubMed ID: 37000341)
1. Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma.
Fotia G; Stellato M; Guadalupi V; Sepe P; Claps M; Giannatempo P; Bottiglieri A; Rametta A; Taglialatela I; Vela C; Procopio G; Verzoni E
Curr Oncol Rep; 2023 Jun; 25(6):671-677. PubMed ID: 37000341
[TBL] [Abstract][Full Text] [Related]
2. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Kovacova J; Poprach A; Buchler T; Cho WC; Slaby O
Clin Chem Lab Med; 2018 Aug; 56(9):1426-1431. PubMed ID: 29451857
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in renal cell carcinoma.
Volpe A; Patard JJ
World J Urol; 2010 Jun; 28(3):319-27. PubMed ID: 20364259
[TBL] [Abstract][Full Text] [Related]
6. Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Studentova H; Hola K; Melichar B; Spisarova M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):339-345. PubMed ID: 38596831
[TBL] [Abstract][Full Text] [Related]
7. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
9. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
10. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
[TBL] [Abstract][Full Text] [Related]
11. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
[No Abstract] [Full Text] [Related]
13. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
14. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
15. Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.
Wang C; Li Y; Chu CM; Zhang XM; Ma J; Huang H; Wang YN; Hong TY; Zhang J; Pan XW; Zheng JC; Jiang N; Hu CY; Ma X; Sun YH; Cui XG
EBioMedicine; 2019 Jan; 39():255-264. PubMed ID: 30558998
[TBL] [Abstract][Full Text] [Related]
16. Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma.
Zhang H; Zhu G
Curr Med Chem; 2021; 28(25):5213-5227. PubMed ID: 33357191
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
[TBL] [Abstract][Full Text] [Related]
18. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and prognostic models for renal cell carcinoma: a literature review.
Klatte T; Rossi SH; Stewart GD
World J Urol; 2018 Dec; 36(12):1943-1952. PubMed ID: 29713755
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib.
Kraljević M; Marijanović I; Barbarić M; Sokolović E; Bukva M; Cerić T; Buhovac T
Biomol Biomed; 2023 Feb; 23(1):161-169. PubMed ID: 35674770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
